Moreover, canertinib, lapatinib, pelitinib, and dacomitinib were confirmed to be effective for NSCLC associated with mutations in EGFR, which can help formulate guidelines for the precise medical treatment of NSCLC involving these mutations. This evidence concerns the gene EGFR and non-small cell lung carcinoma.